Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
The above chart is not meant for medical diagnosis purposes
Only four of 23 have rated NOV shares a Buy, although the stock has 50% upside potential based on a consensus price target of $65.56
Hunger isnt a mystery
Neurotrophic factorsa tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases
Exenatide (including extended-release formulations) Therapeutic Benefits 1
US$ 20.15
US$ 22.38
US$ 27.77
US$ 24.53
US$ 27.04
US$ 24.14
US$ 27.25
US$ 20.45
